ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.

Asymchem Laboratories (Tianjin) Co., Ltd.

002821

CNE100002BZ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
76.6 ^CNY	-2.31%		-0.78%	-34.02%

Apr. 02	Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	CI
Mar. 29	Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023	MT

Asymchem Laboratories Co., Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021

March 30, 2022 at 09:59 am EDT

Asymchem Laboratories (Tianjin) Co., Ltd. proposed final cash dividend of RMB 8 per 10 share for the year ended December 31, 2021. Date of shareholders' approval is 09 June 2022.

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	Apr. 02	CI
Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023	Mar. 29	MT
Asymchem Laboratories Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023	Mar. 28	CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Asymchem Laboratories Completes A-Share Repurchase Program	Mar. 27	MT
Asymchem Laboratories Co., Ltd. commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024.	Mar. 07	CI
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy	Mar. 04	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy	Mar. 04	MT
Asymchem Laboratories Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024	Feb. 29	CI
Asymchem Laboratories Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees	Feb. 05	CI
Asymchem's Shenzhen Shares Jump 7% on 1.2 Billion Yuan Stock Buyback	Feb. 01	MT
INSTANT VIEW 8-China Evergrande ordered to liquidate by Hong Kong court	Jan. 29	RE
Chinese Shares Retreat to Four-Year Lows Ahead of Trade, Inflation Data; Bolong Equipment Surges 17% in Shanghai Debut	Jan. 10	MT
China's policy dilemma: is boosting credit deflationary?	Jan. 10	RE
Asymchem Laboratories To Buy Back Over 100,000 Shares	Dec. 26	MT
Chinese Shares End Lower as Economic Roadmap Disappoints; Fengmao Technology Surges 86% in Shenzhen Debut	Dec. 13	MT
Asymchem Laboratories Records 47% Drop in Q3 Profit	23-10-31	MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$134.59 From HK$130.30, Keeps at Buy	23-10-25	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 189.98 Yuan From 160.07 Yuan, Keeps at Buy	23-10-25	MT
Asymchem Laboratories Co., Ltd. Appoints Sun Xuejiao as Independent Non-Executive Director	23-09-13	CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
China stocks rise on support steps but off early highs amid broader economic concerns	23-08-28	RE
China's stocks, yuan fall as Beijing's support fails to impress	23-08-20	RE
Yellen raised China's hopes for tariff cut; U.S. politics will crush them	23-07-12	RE

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Duration

Period

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

More charts

Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The Company's main businesses are the process development, amplification and commercialization of chemical drugs. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

76.6 CNY

Average target price

114.9 CNY

Spread / Average Target

+50.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.	-34.02%	3.81B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

Asymchem Laboratories (Tianjin) Co., Ltd.

Equities

002821

CNE100002BZ6

Pharmaceuticals

Asymchem Laboratories Co., Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals